Editorial: Towards a mechanistic understanding of depression, anxiety, and their comorbidity: perspectives from cognitive neuroscience

From Lab to Life: Exploring Cutting-Edge Models for Neurological and Psychiatric Disorders

“…Despite the advances in neuroscience and neurology, the etiology and pathogenesis of these disorders remain largely unknown, and contemporary treatments are often inadequate or associated with adverse effects [ 88 , 89 , 90 , 91 ]. Therefore, there is an urgent need to develop new and effective strategies to prevent, diagnose, and treat these disorders [ 92 , 93 , 94 ]. To achieve this goal, it is essential to establish reliable and relevant models that can recapitulate the complex interactions between the genetic, epigenetic, environmental, and pharmacological factors that contribute to the onset and progression of these disorders [ 95 , 96 , 97 ].…”

The Impact of C-3 Side Chain Modifications on Kynurenic Acid: A Behavioral Analysis of Its Analogs in the Motor Domain

“…The CNS plays a critical role in regulating essential functions such as cognition, motion, and emotion [ 123 , 124 , 125 , 126 ]. However, they are susceptible to various disorders that impair their function [ 4 , 5 , 6 , 127 , 128 , 129 , 130 , 131 ].…”

Emerging Translational Research in Neurological and Psychiatric Diseases: From In Vitro to In Vivo Models

“…In this multidisciplinary endeavor, neuropharmacological research plays a pivotal role. The study of how drugs and compounds interact with the intricate neural networks present in preclinical models provides a deeper understanding of potential therapeutic agents [62][63][64][65][66][67][68][69]. These insights guide the future development of pharmacological interventions that can target the specific molecular pathways implicated in neuropsychiatric conditions.…”